PDCD1 and hepatocellular carcinoma: Another study explored hepatocellular carcinoma (HCC) in 42 patients who received either nivolumab monotherapy or anti-PD-1 (pembrolizumab) in combination with anti-CTLA-4 (ipilimumab).